Nalaganje...
Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
The epidermal growth factor receptor (EGFR) secondary kinase domain T790M non–small cell lung cancer (NSCLC) mutation enhances receptor catalytic activity and confers resistance to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. Currently, irreversible inhibitors represent the pri...
Shranjeno v:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2008
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3272303/ https://ncbi.nlm.nih.gov/pubmed/18632637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-07-5428 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|